New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 3, 2014
09:09 EDTCURNeuralstem raises $19.65M in a registered direct offering
Neuralstem announced that it has entered into agreements with leading institutional investors for a registered direct placement of 6,752,744 shares of common stock at a price of $2.91 per share, resulting in aggregate gross proceeds of approximately $19.65 million. T.R. Winston & Company, LLC acted as the exclusive placement agent for the offering.
News For CUR From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
June 29, 2015
09:23 EDTCURNeuralstem announces approving for listing on Nasdaq
Subscribe for More Information
June 26, 2015
07:33 EDTCURNeuralstem announces preclinical data of HK532-IGF-1 stem cells
Neuralstem announced that the poster "Human Neural Stem Cells Expressing IGF-1: A Novel Cellular Therapy for Alzheimer's Disease" was presented yesterday at the International Society for Stem Cell Research Annual Meeting. In the poster, researchers from the University of Michigan presented data that mice with an animal model of Alzheimer's disease, transplanted with HK532-IGF-1 cells in the peri-hippocampus, performed better on hippocampal-dependent behavioral tasks than untreated mice, demonstrating both enhanced learning cognitive processes and memory consolidation. Researchers also reported a beta-amyloid plaque reduction in both the cortex and hippocampus of the mice that received the stem cells. Amyloid plaque is one of the two hallmarks of AD. These results indicate that HK532-IGF-1 transplantation can impact learning and memory deficits, as well as Alzheimer's pathology. The researchers found the results to be encouraging and recommend further study. HK532-IGF-1, Neuralstem's second stem cell line, is a proprietary line of cortical neural stem cells engineered to express insulin-like growth factor-1, which has been shown to have wide-ranging neuroprotective properties.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use